These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30762670)

  • 101. A case of visible diffuse peritoneal Bacillus Calmette-Guérin infection at the time of planned radical cystectomy.
    Nielsen MØ; Elversang J; Martin Poulsen A; Persson Theilgaard Z; Joensen UN
    Scand J Urol; 2021 Dec; 55(6):505-506. PubMed ID: 34470576
    [No Abstract]   [Full Text] [Related]  

  • 102. Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
    Mukherjee N; Svatek RS; Mansour AM
    Urol Oncol; 2018 Mar; 36(3):103-108. PubMed ID: 29429897
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer.
    Raj GV; Herr H; Serio AM; Donat SM; Bochner BH; Vickers AJ; Dalbagni G
    J Urol; 2007 Apr; 177(4):1283-6; discussion 1286. PubMed ID: 17382713
    [TBL] [Abstract][Full Text] [Related]  

  • 104. The challenge of Bacillus Calmette-Guérin failure in nonmuscle invasive bladder cancer--what is the next step in management?
    Lotan Y
    J Urol; 2013 Sep; 190(3):832-3. PubMed ID: 23791573
    [No Abstract]   [Full Text] [Related]  

  • 105. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial.
    Di Lorenzo G; Perdonà S; Damiano R; Faiella A; Cantiello F; Pignata S; Ascierto P; Simeone E; De Sio M; Autorino R
    Cancer; 2010 Apr; 116(8):1893-900. PubMed ID: 20162706
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897).
    Van der Meijden AP; Hall RR; Macaluso MP; Pawinsky A; Sylvester R; Van Glabbeke M
    Eur Urol; 1996; 29(2):199-203. PubMed ID: 8647147
    [TBL] [Abstract][Full Text] [Related]  

  • 107. [Classification, favorable characteristics, prevention and treatment of adverse side-effects associated with Bacillus Calmette-Guerin in the treatment of superficial bladder cancer].
    Saint F; Salomon L; Quintela R; Cicco A; Abbou CC; Chopin DK
    Ann Urol (Paris); 2002 Mar; 36(2):120-31. PubMed ID: 11969046
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Palliative effect of intravesical bacillus Calmette-Guerin in elderly patients with advanced bladder carcinoma.
    Holmäng S; Fehrling M; Hedelin H
    J Urol; 1997 Sep; 158(3 Pt 1):812-3. PubMed ID: 9258088
    [TBL] [Abstract][Full Text] [Related]  

  • 109. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K; Chihara Y; Kondo H; Hirao Y
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Effect of keyhole limpet hemocyanin (KLH) and bacillus Calmette-Guérin (BCG) instillation on carcinoma in situ of the urinary bladder.
    Jurincic-Winkler C; Metz KA; Beuth J; Sippel J; Klippel KF
    Anticancer Res; 1995; 15(6B):2771-6. PubMed ID: 8669862
    [TBL] [Abstract][Full Text] [Related]  

  • 111. A systematic review of preventive and therapeutic options for symptoms of cystitis in patients with bladder cancer receiving intravesical bacillus Calmette-Guérin immunotherapy.
    Poletajew S; Krajewski W; Adamowicz J; Radziszewski P
    Anticancer Drugs; 2019 Jun; 30(5):517-522. PubMed ID: 30870228
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette-Guérin shortage.
    Fankhauser CD; Teoh JY; Mostafid H
    Curr Opin Urol; 2020 May; 30(3):365-369. PubMed ID: 32141939
    [TBL] [Abstract][Full Text] [Related]  

  • 113. New agents for bacillus Calmette-Guérin-refractory bladder cancer.
    Ahn JJ; McKiernan JM
    Urol Clin North Am; 2013 May; 40(2):219-32. PubMed ID: 23540780
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy.
    Yates DR; Rouprêt M
    World J Urol; 2011 Aug; 29(4):415-22. PubMed ID: 21544661
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Sequential intravesical gemcitabine and docetaxel therapy in patients with nonmuscle invasive bladder cancer: a systematic review and meta-analysis.
    Kawada T; Yanagisawa T; Araki M; Pradere B; Shariat SF
    Curr Opin Urol; 2023 May; 33(3):211-218. PubMed ID: 36482766
    [TBL] [Abstract][Full Text] [Related]  

  • 116. [Recurrence and progression after BCG.].
    Lendínez-Cano G; Rivero-Belenchón I; Medina-López RA
    Arch Esp Urol; 2020 Dec; 73(10):929-933. PubMed ID: 33269711
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Severe Infectious Complications of Intravesical Bacillus Calmette-Guérin: A Case Series of 10 Patients.
    Yong C; Steinberg RL; O'Donnell MA
    Urology; 2020 Mar; 137():79-83. PubMed ID: 31705946
    [TBL] [Abstract][Full Text] [Related]  

  • 118. The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience.
    Barlow LJ; McKiernan JM; Benson MC
    World J Urol; 2009 Jun; 27(3):331-5. PubMed ID: 19214528
    [TBL] [Abstract][Full Text] [Related]  

  • 119. BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know?
    Lebacle C; Loriot Y; Irani J
    World J Urol; 2021 Nov; 39(11):4037-4046. PubMed ID: 33772322
    [TBL] [Abstract][Full Text] [Related]  

  • 120. The Who, What, When, Where, and Why of Bacillus Calmette-Guérin-unresponsive Bladder Cancer.
    Li R; Lerner SP; Kamat AM
    Eur Urol; 2021 Apr; 79(4):437-439. PubMed ID: 33454163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.